Purple Biotech Issues Letter to Shareholders

REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor

Related Keywords

United States ,Israel ,Rehovot ,Hamerkaz ,Texas ,American ,Gil Efron ,Robert Gagnon ,Bristol Myers Squibb ,Suzana Nahum Zilberberg ,Exchange Commission ,Department Of Cancer Biology ,University Of Texas Md Anderson Cancer Center ,Company Contact ,Purple Biotech Ltd ,Drug Administration ,Purple Biotech ,Chief Executive Officer ,Isaac Israel ,Cancer Center ,Menashe Bar Eli ,Cancer Biology ,Ori Hershkovitz ,Fabien Sebille ,Chief Business ,Chief Executive Officer Purple ,Looking Statements ,Safe Harbor ,Private Securities Litigation Reform Act ,Annual Report ,Registration Statements ,Money ,Ational ,